Research Analysts Set Expectations for STOK FY2029 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Analysts at Wedbush issued their FY2029 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a research note issued on Tuesday, January 7th. Wedbush analyst L. Chico expects that the company will post earnings of ($0.41) per share for the year. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.03) per share.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.05. The company had revenue of $4.89 million for the quarter, compared to analyst estimates of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.

Other equities analysts also recently issued research reports about the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Leerink Partners began coverage on Stoke Therapeutics in a research note on Monday, October 14th. They set an “outperform” rating and a $18.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday. Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th. Finally, Chardan Capital initiated coverage on shares of Stoke Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating and a $24.00 price target for the company. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Stoke Therapeutics currently has an average rating of “Buy” and an average target price of $21.29.

Stoke Therapeutics Price Performance

NASDAQ STOK opened at $9.00 on Thursday. The firm’s fifty day moving average price is $11.91 and its 200 day moving average price is $13.04. Stoke Therapeutics has a 12 month low of $4.09 and a 12 month high of $17.58. The company has a market capitalization of $476.70 million, a price-to-earnings ratio of -4.29 and a beta of 0.95.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. The Manufacturers Life Insurance Company lifted its holdings in Stoke Therapeutics by 16.7% in the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after acquiring an additional 1,994 shares during the period. Quest Partners LLC acquired a new stake in shares of Stoke Therapeutics in the second quarter valued at about $29,000. Los Angeles Capital Management LLC boosted its holdings in Stoke Therapeutics by 7.2% during the second quarter. Los Angeles Capital Management LLC now owns 66,765 shares of the company’s stock worth $902,000 after buying an additional 4,508 shares in the last quarter. Rhumbline Advisers grew its position in Stoke Therapeutics by 14.3% during the second quarter. Rhumbline Advisers now owns 47,860 shares of the company’s stock worth $647,000 after buying an additional 5,990 shares during the period. Finally, Intech Investment Management LLC purchased a new position in Stoke Therapeutics in the third quarter valued at about $160,000.

Insider Activity

In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 6,170 shares of the business’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $12.78, for a total transaction of $78,852.60. Following the transaction, the chief executive officer now owns 68,671 shares in the company, valued at approximately $877,615.38. The trade was a 8.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, General Counsel Jonathan Allan sold 13,666 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $13.61, for a total value of $185,994.26. Following the transaction, the general counsel now directly owns 21,476 shares of the company’s stock, valued at approximately $292,288.36. This trade represents a 38.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 62,849 shares of company stock valued at $809,421. Company insiders own 11.30% of the company’s stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.